Hua Medicine (Stock Code: 02552, “Hua Medicine”) has convened its 2026 Annual General Meeting (AGM) for 25 June 2026 at 10:30 a.m. in the company’s Shanghai headquarters (Building 2, Lane 36, Xuelin Road, Pudong New Area). Key agenda items are as follows:

1. Review of FY 2025 Results • Shareholders will receive and consider the audited consolidated financial statements and the reports of directors and auditors for the year ended 31 December 2025. • Deloitte Touche Tohmatsu is nominated for re-appointment as external auditor, with the board authorised to determine remuneration.

2. Board Composition and Remuneration • Re-election proposals cover Executive Director Dr Yi Zhang, Non-Executive Director Mr Robert Taylor Nelsen and Independent Non-Executive Director Mr William Robert Keller. • The board seeks authority to set directors’ remuneration.

3. Capital Management Mandates • Share Repurchase: A general mandate to repurchase up to 10% of issued shares (excluding any treasury shares) during the mandate period. • Share Issuance: A general mandate to allot, issue or deal with additional shares and/or resell treasury shares up to 20% of issued share capital (excluding treasury shares). • Mandate Extension: Conditional on the above, the issuance mandate may be extended by the number of shares repurchased, effectively adding up to a further 10% capacity.

4. Governance Update • Shareholders will vote on adopting the Fourth Amended and Restated Memorandum and Articles of Association, replacing the current version.

5. Key Administrative Dates • Register of Members closure: 22 June – 25 June 2026 (both days inclusive). • Deadline for share transfers to qualify for AGM attendance and voting: 18 June 2026, 4:30 p.m. • Proxy form submission deadline: 23 June 2026, 10:30 a.m.

Hua Medicine highlights that all resolutions will be decided by poll and encourages shareholders to appoint the meeting chairman as proxy if physical attendance is not feasible. Queries can be directed to the company’s Hong Kong share registrar, Tricor Investor Services Limited, or via email to ir@huamedicine.com.